Drugmaker Biophore India Pharmaceuticals has obtained Central Drugs Standard Control Organisation (CDSCO) approval for manufacturing and advertising and marketing of Cannabidiol active ingredient in India.
The firm’s subsidiary Zenara Pharma has obtained approval for the ultimate product, Cannabidiol Oral Solution 100mg/ml, indicated for neuro issues.
It is for the primary time {that a} Cannabidiol-based product has been authorised in India. The product is being manufactured at U.S. FDA and EU authorised state-of-the-art amenities in Hyderabad and Visakhapatnam. Preparations are underway for the launch of the product, in 4 months, by collaborating with like-minded organisations in India, together with Akums Drugs & Pharmaceuticals, Biophore stated.
Zenara and Biophore have developed Cannabidiol fully by way of artificial route and the identical product has been filed with the U.S. FDA for approval.
The active ingredient had already been registered with the U.S. FDA final 12 months.
The CDSCO approval is for therapy of seizures related to Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complicated in sufferers one 12 months of age or older. Cannabidiol is already authorised within the U.S. for these indications, the corporate stated in a launch.
“We continue to invest in such first-of-its-kind product for the Indian market and we will see more of them in the coming years,” Biophore CEO Jagadeesh Babu Rangisetty stated.
